-
FXR–KLF11 Signaling in Contrast-Induced Kidney Injury
2026-09-24
A 2026 preclinical study reports that Chenodeoxycholic Acid activates FXR, which directly upregulates KLF11 and suppresses JAK2/STAT3 signaling in contrast-induced acute kidney injury models. The findings connect nuclear receptor transcriptional control to renal inflammation and apoptosis, while leaving dose optimization, safety, and clinical efficacy to future studies.
-
Angiotensin 1/2 (2-7): Assay Workflows & Uses
2026-09-24
Use this angiotensin peptide fragment to build controlled binding assays at the intersection of renin-angiotensin biology and SARS-CoV-2 spike–receptor research. The article separates published findings from practical pilot conditions, with workflow controls and troubleshooting guidance for reproducible results.
-
FLAG tag Peptide for HDAC Workflows
2026-09-23
Build cleaner recombinant HDAC purification, detection, and activity assays with a soluble DYKDDDDK peptide that supports gentle competitive elution. The workflow also shows how to separate affinity-tag handling from the biochemical conclusions of Sin3L/Rpd3L complex experiments.
-
EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Assay Guide
2026-09-22
Learn how EZ Cap™ Mouse IL-12 mRNA (m1Ψ) can support rigorous cytokine expression, delivery, and immune-function studies. This guide connects transcript design with EVMP-based extrahepatic delivery while emphasizing controls, readouts, and translational limitations.
-
SVP3 Hetero-Galactan and Hypolipidemic Activity
2026-09-22
The reference study purified SVP3, a structurally defined neutral hetero-galactan from Sanghuangporus vaninii, and linked its activity to improved lipid phenotypes and suppression of inflammation-associated TLR4/NF-κB signaling in hyperlipidemic mice. Its integrated use of polysaccharide structural analysis, gut microbiota profiling, serum metabolomics, and liver proteomics provides a useful framework for evaluating natural macromolecules as candidates for metabolic research.
-
EZ Cap™ Mouse IL-12 mRNA Workflow Guide
2026-09-21
Build reproducible IL-12 expression assays with a capped, polyadenylated, m1Ψ-modified transcript designed for efficient protein production and reduced innate immune stimulation. This guide connects practical cytokine-expression workflows with circRNA vaccine research while clearly separating established product features from optimization starting points.
-
Latrunculin B: Reliable Actin Assays
2026-09-21
This scenario-driven guide explains how Latrunculin B (SKU C5804) can improve interpretation of viability, proliferation, and cytoskeletal assays through mechanism-aware design and careful handling. It also defines the compound’s experimental boundaries, including evidence that it does not universally block viral entry.
-
Anagliptin Vasorelaxation: Kv Channels and SERCA
2026-09-20
A 2025 Acta Diabetologica study shows that anagliptin produces dose-dependent relaxation of phenylephrine-contracted rabbit aortic rings through pharmacologically sensitive Kv channels and the SERCA pump. The work extends research on SK-0403 beyond glycemic pharmacology while carefully separating this vascular response from endothelium-dependent, cAMP/PKA, and cGMP/PKG signaling.
-
Sulfaphenazole-Derived Sulfonamides Against M. tuberculosis
2026-09-19
The reference study optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing unwanted CYP2C9 inhibition. Compound 10d emerged as a useful lead, combining a MIC of 5.69 μg/mL with CYP2C9 inhibition above 10 μM and low cytotoxicity.
-
Mitoxantrone Workflows for ABCG2 Resistance Studies
2026-09-19
Build reproducible Mitoxantrone assays for DNA-damage response, apoptosis, and ABCG2-mediated drug resistance. This workflow combines concentration-aware handling with intracellular accumulation and chemosensitization readouts, extending the compound’s value beyond a conventional viability assay.
-
Fucoidan and Cancer Plasticity: An Assay Guide
2026-09-18
Fucoidan is examined here as a sulfated α-L-fucan whose cancer effects require more than a single viability readout. This article translates apoptosis, immune, angiogenic, and cellular-plasticity evidence into a practical assay framework grounded in the cited NPC differentiation study.
-
AZD0156: ATM Kinase Inhibitor Workflow
2026-09-18
AZD0156 enables selective ATM pathway perturbation for DNA repair, checkpoint, and combination cancer therapy research. This workflow translates evidence linking ATM inhibition with fenofibrate sensitivity into practical dose-response, synergy, biomarker, and senescence assays.
-
VE-821 ATR Kinase Inhibitor Workflow
2026-09-17
Build reproducible ATR inhibition, DNA damage, radiosensitization, and chemotherapy-sensitization experiments with VE-821. The workflow also explains how to use the compound as a carefully bounded DDR comparison tool when interpreting DNMT1-centered HBoV1 research.
-
CTCF Maintains Centromere Function in Mitosis
2026-09-17
The reference study uses rapid auxin-inducible degradation to show that CTCF is required for centromere organization, accurate chromosome alignment, and mitotic fidelity. Its findings distinguish CTCF loss from direct CENP-E disruption and support a model in which CTCF helps maintain centromeric chromatin architecture, possibly through functions related to cohesin.
-
ZCL278: From Cdc42 Assays to Fibrosis Models
2026-09-16
ZCL278 is a selective Cdc42 inhibitor for dissecting GTPase-dependent motility, cytoskeletal remodeling, and signaling. This article connects its cellular assay behavior with the 2024 kidney-fibrosis study and explains how to design stronger target-engagement workflows without overstating translational evidence.